ArticleJournal of thoracic disease2023
Expression and significance of serum KL-6 in patients with acute respiratory distress syndrome.
Article in Journal of thoracic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
- Serum KL-6 and the mortality of patients with connective tissue disease-associated interstitial lung disease: A meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- Current Insights into Clinical, Molecular, and Therapeutic Approaches to Acute Respiratory Distress Syndrome.Medical sciences (Basel, Switzerland) · 2026Review
- Circulating and Respiratory Biomarkers in Sepsis-Induced ARDS: Diagnostic and Prognostic Insights - A Narrative Review.Journal of inflammation research · 2026Review
- LIPS and PaOMediators of inflammation · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute respiratory distress syndrome (ARDS) is a common and serious complication that occurs in the ICU. the determination of early ARDS indicators, along with timely treatment, can potentially diminish medical costs and reduce ARDS-related mortality. In this report, we evaluated the clinical significance of circulating Krebs von den Lungen-6 (KL-6) content among patients with intra- and extrapulmonary ARDS to investigate the clinical significance of serum KL-6. Methods: Patients who met the ARDS Berlin criteria and were hospitalized in the intensive care unit of the China-Japan Union Hospital of Jilin University between September 2021 and September 2022 were recruited for analysis. ARDS patients were divided into an intrapulmonary ARDS group (n=23) and an extrapulmonary ARDS group (n=27) based on their primary diagnosis. Baseline demographic data, including age and sex, and clinical data, including underlying diseases and mortality, of the two groups were collected and analyzed. Peripheral venous blood was collected on Day 0 (baseline), Day 1, Day 3, and Day 7. The kinetic levels of serum KL-6 were compared between patients who survived and those who died within one week of ARDS diagnosis. The prognosis, survival times, and status of patients within 28 days after diagnosis were evaluated. Results: In the intrapulmonary ARDS group, patients who died had significantly higher serum KL-6 levels in the seven days following diagnosis than those who survived. In contrast, in the extrapulmonary group, the difference in KL-6 values between patients who survived and died was only significant on the first day after diagnosis. The peak levels of serum KL-6 in the death group were significantly higher than those in the survival group for both intra- and extrapulmonary ARDS (P=0.0253). The optimal cutoff value of the serum KL-6 level was 1,452.3 U/mL in intrapulmonary ARDS patients and 828.2 U/mL in extrapulmonary patients. Serum KL-6 levels higher than the cutoff levels were confirmed to be a significant prognostic predictor of poor survival within 28 days of diagnosis in patients with intra- and extrapulmonary ARDS. Conclusions: The serum KL-6 level is potentially a good indicator for predicting the prognosis of patients with ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.